LinkedIn Profile

Access K-PAX Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:k-paxpharmaceuticals 1341054 Nov 7th, 2017 12:00AM K-PAX Pharmaceuticals 84 5.00 Open Pharmaceuticals Nov 7th, 2017 04:57PM Nov 7th, 2017 04:57PM K-PAX Pharmaceuticals is a privately held biotech company currently developing proprietary compounds to treat fatigue, decreased alertness and decreased cognition in Parkinson's disease, Alzheimer’s disease, and cancer-related fatigue. Our patented compound - KPAX002 - is a proprietary modified version of methylphenidate. It is an enhanced, safer CNS stimulant, bolstered by our proprietary mitochondrial technology, with the ability to safely alleviate fatigue and decreased alertness in patients with neurodegenerative and other serious diseases. We have completed several clinical trials which demonstrate that KPAX002 has excellent safety and efficacy at alleviating severe fatigue and decreased alertness symptoms in chronically ill patients. This indication represents a serious unmet medical need with a large population. The FDA is highly supportive of identifying a fatigue treatment in multiple disease states. We are concurrently pursuing several regulatory indications: 1) Parkinson's disease non-motor symptoms 2) Alzheimer's disease decreased alertness 3) Cancer-related fatigue 4) Myalgic encephalomyelitis K-PAX Pharmaceuticals Health Care Health Care Equipment & Services
private:k-paxpharmaceuticals 1341054 Nov 1st, 2017 12:00AM K-PAX Pharmaceuticals 83 5.00 Open Pharmaceuticals Nov 1st, 2017 04:43AM Nov 1st, 2017 04:43AM K-PAX Pharmaceuticals is a privately held biotech company currently developing proprietary compounds to treat fatigue, decreased alertness and decreased cognition in Parkinson's disease, Alzheimer’s disease, and cancer-related fatigue. Our patented compound - KPAX002 - is a proprietary modified version of methylphenidate. It is an enhanced, safer CNS stimulant, bolstered by our proprietary mitochondrial technology, with the ability to safely alleviate fatigue and decreased alertness in patients with neurodegenerative and other serious diseases. We have completed several clinical trials which demonstrate that KPAX002 has excellent safety and efficacy at alleviating severe fatigue and decreased alertness symptoms in chronically ill patients. This indication represents a serious unmet medical need with a large population. The FDA is highly supportive of identifying a fatigue treatment in multiple disease states. We are concurrently pursuing several regulatory indications: 1) Parkinson's disease non-motor symptoms 2) Alzheimer's disease decreased alertness 3) Cancer-related fatigue 4) Myalgic encephalomyelitis K-PAX Pharmaceuticals Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.